These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

593 related items for PubMed ID: 14724439

  • 1. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy.
    Clave E, Agbalika F, Bajzik V, Peffault de Latour R, Trillard M, Rabian C, Scieux C, Devergie A, Socié G, Ribaud P, Adès L, Ferry C, Gluckman E, Charron D, Esperou H, Toubert A, Moins-Teisserenc H.
    Transplantation; 2004 Jan 15; 77(1):76-84. PubMed ID: 14724439
    [Abstract] [Full Text] [Related]

  • 2. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B.
    J Med Virol; 2008 Mar 15; 80(3):441-54. PubMed ID: 18205222
    [Abstract] [Full Text] [Related]

  • 3. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K.
    Scand J Infect Dis; 2007 Mar 15; 39(3):235-44. PubMed ID: 17366054
    [Abstract] [Full Text] [Related]

  • 4. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 15; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 5. Preemptive management of Epstein-Barr virus reactivation after hematopoietic stem-cell transplantation.
    Ahmad I, Cau NV, Kwan J, Maaroufi Y, Meuleman N, Aoun M, Lewalle P, Martiat P, Crokaert F, Bron D.
    Transplantation; 2009 Apr 27; 87(8):1240-5. PubMed ID: 19384173
    [Abstract] [Full Text] [Related]

  • 6. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM, Gharib MI, Turner AJ, Guiver M, Carr T, Will AM, Wynn RF.
    Pediatr Blood Cancer; 2006 Aug 27; 47(2):200-5. PubMed ID: 16206207
    [Abstract] [Full Text] [Related]

  • 7. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation.
    Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E, Tridello G, Varotto S, Alaggio R, Zanesco L, Palù G, Messina C.
    Br J Haematol; 2005 Jan 27; 128(2):224-33. PubMed ID: 15638858
    [Abstract] [Full Text] [Related]

  • 8. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S, Behnke-Hall K, Gruhn B, Bauer J, Horn M, Beck J, Reiter A, Wagner HJ.
    J Clin Virol; 2012 Mar 27; 53(3):186-94. PubMed ID: 22182950
    [Abstract] [Full Text] [Related]

  • 9. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.
    Biol Blood Marrow Transplant; 2011 Jun 27; 17(6):901-7. PubMed ID: 20950702
    [Abstract] [Full Text] [Related]

  • 10. High level of perforin expression in T cells: An early prognostic marker of the severity of herpesvirus reactivation after allogeneic stem cell transplantation in adults.
    Pietersma FL, van Dorp S, Jacobi R, Ran L, Nanlohy NM, Schuurman R, Minnema MC, Meijer E, van Baarle D.
    Clin Infect Dis; 2010 Mar 01; 50(5):717-25. PubMed ID: 20121571
    [Abstract] [Full Text] [Related]

  • 11. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
    Lu Y, Wu T, Cao XY, Wang JB, Sun Y, Zhao YL, DA WM, Ji SQ, Tong CR, Lu DP.
    Zhonghua Nei Ke Za Zhi; 2011 May 01; 50(5):383-7. PubMed ID: 21624219
    [Abstract] [Full Text] [Related]

  • 12. [EBV quantification in children after allogeneic hematopoietic stem cell transplantation].
    Hubácek P, Cinek O, Kulich M, Zajac M, Keslová P, Formánková R, Starý J, Sedlácek P.
    Cas Lek Cesk; 2006 May 01; 145(4):301-6. PubMed ID: 16639931
    [Abstract] [Full Text] [Related]

  • 13. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
    Carpenter B, Haque T, Dimopoulou M, Atkinson C, Roughton M, Grace S, Denovan S, Fielding A, Kottaridis PD, Griffiths P, Mackinnon S, Emery V, Chakraverty R.
    Transplantation; 2010 Sep 15; 90(5):564-70. PubMed ID: 20555307
    [Abstract] [Full Text] [Related]

  • 14. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation.
    Nolte A, Buhmann R, Straka C, Emmerich B, Hallek M.
    Bone Marrow Transplant; 1998 May 15; 21(9):909-16. PubMed ID: 9613783
    [Abstract] [Full Text] [Related]

  • 15. Viral-load and B-lymphocyte monitoring of EBV reactivation after allogeneic hemopoietic SCT in children.
    Faraci M, Caviglia I, Morreale G, Lanino E, Cuzzubbo D, Giardino S, Di Marco E, Cirillo C, Scuderi F, Dallorso S, Terranova P, Moroni C, Castagnola E.
    Bone Marrow Transplant; 2010 Jun 15; 45(6):1052-5. PubMed ID: 19855442
    [Abstract] [Full Text] [Related]

  • 16. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
    Merlino C, Giacchino F, Bergallo M, Bonello F, Bollero C, Segoloni GP, Cavallo R.
    G Ital Nefrol; 2003 Jun 15; 20(2):170-5. PubMed ID: 12746803
    [Abstract] [Full Text] [Related]

  • 17. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN, Tang AZ, Zhou L, Huang GW, Wang Z, Zeng Y.
    Chin Med J (Engl); 2009 May 20; 122(10):1173-8. PubMed ID: 19493466
    [Abstract] [Full Text] [Related]

  • 18. Longitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation.
    Vogl BA, Fagin U, Nerbas L, Schlenke P, Lamprecht P, Jabs WJ.
    J Med Virol; 2012 Jan 20; 84(1):119-31. PubMed ID: 22095540
    [Abstract] [Full Text] [Related]

  • 19. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation.
    Gruhn B, Meerbach A, Häfer R, Zell R, Wutzler P, Zintl F.
    Bone Marrow Transplant; 2003 Jun 20; 31(11):1023-5. PubMed ID: 12774054
    [Abstract] [Full Text] [Related]

  • 20. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution.
    Annels NE, Kalpoe JS, Bredius RG, Claas EC, Kroes AC, Hislop AD, van Baarle D, Egeler RM, van Tol MJ, Lankester AC.
    Clin Infect Dis; 2006 Jun 15; 42(12):1743-8. PubMed ID: 16705581
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.